New stock news | Di Zhe Medicine (688192.SH) submits documents to the Hong Kong Stock Exchange

According to the disclosure on January 23 by the Hong Kong Stock Exchange, Dejia (Jiangsu) Pharmaceutical Co., Ltd. (referred to as Dejia Pharmaceutical (688192.SH)) has submitted its listing application to the main board of the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as its joint sponsors. According to the prospectus, Dejia Pharmaceutical is a commercial-stage biopharmaceutical company, with its core therapeutic areas being tumors and hematologic diseases. The company's listed product, Savolert is the only small molecule epidermal growth factor receptor tyrosine kinase inhibitor approved globally for the treatment of EGFR 20 exon insertion mutation-type lung cancer.